IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/imax-china-holding-inc" target="_blank" data-smartkarma-citation="entities:888:1" rel="noopener">IMAX China Holding (1970 HK)</a>'s scheme document is out, with the court meeting scheduled for 10 October. The IFA considers <a href="https://www.smartkarma.com/entities/imax-corp" target="_blank" data-smartkarma-citation="entities:5321:1" rel="noopener">IMAX Corp (IMAX US)</a>'s HK$10.00 offer fair and reasonable.</li>
<li>The key condition is approval by at least 75% of disinterested shareholders (&lt;10% of all disinterested shareholders rejection). No independent shareholder holds a blocking stake. </li>
<li>A recovering box office, early indications of an effort to rally retail NO votes and a high minority participation rate in AGMs pose a risk. The risk/reward profile is unfavourable. </li>
</ul>



IMAX China Holding (1970 HK)'s scheme document is out, with the court meeting scheduled for 10 October. The IFA considers IMAX Corp (IMAX US)'s HK$10.00 offer fair and reasonable.
The key condition is approval by at least 75% of disinterested shareholders (&lt;10% of all disinterested shareholders rejection). No independent shareholder holds a blocking stake. 
A recovering box office, early indications of an effort to rally retail NO votes and a high minority participation rate in AGMs pose a risk. The risk/reward profile is unfavourable. 


IMAX China (1970 HK): Risk as Scheme Vote on 10 October

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

<ul>
<li>Back on the 13 July, <a href="https://www.smartkarma.com/entities/imax-china-holding-inc" target="_blank" data-smartkarma-citation="entities:888:1" rel="noopener">IMAX China Holding (1970 HK)</a> announced a take-private transaction from its parent <a href="https://www.smartkarma.com/entities/imax-corp" target="_blank" data-smartkarma-citation="entities:5321:1" rel="noopener">IMAX Corp (IMAX US)</a> at HK$10/share. Terms have been declared final.</li>
<li>The price is a 9.65% premium to last close but a 39.47% premium over the closing price on the last full trading day, suggesting apparent news leakage.</li>
<li>The Scheme Doc is out and independent shareholders get to vote on the transaction on the 10th October. This vote could - should - be close. Only for the brave.</li>
</ul>


Back on the 13 July, IMAX China Holding (1970 HK) announced a take-private transaction from its parent IMAX Corp (IMAX US) at HK$10/share. Terms have been declared final.
The price is a 9.65% premium to last close but a 39.47% premium over the closing price on the last full trading day, suggesting apparent news leakage.
The Scheme Doc is out and independent shareholders get to vote on the transaction on the 10th October. This vote could - should - be close. Only for the brave.


IMAX China (1970 HK)'s Offer: 10th Oct Shareholder Vote

<ul>
<li>
<a href="https://www.smartkarma.com/entities/imax-china-holding-inc" target="_blank" data-smartkarma-citation="entities:888:1" rel="noopener">IMAX China Holding (1970 HK)</a> disclosed a scheme privatisation offer from <a href="https://www.smartkarma.com/entities/imax-corp" target="_blank" data-smartkarma-citation="entities:5321:1" rel="noopener">IMAX Corp (IMAX US)</a> at HK$10.00 per share, a 39.5% premium to the undisturbed price (HK$7.17 on 10 July).</li>
<li>The key condition is approval by at least 75% of disinterested shareholders (&lt;10% of all disinterested shareholders rejection). No independent shareholder holds a blocking stake. </li>
<li>The offer price is final. While the offer price is light compared to peer multiples and historical share prices, the deal will likely succeed. </li>
</ul>



IMAX China Holding (1970 HK) disclosed a scheme privatisation offer from IMAX Corp (IMAX US) at HK$10.00 per share, a 39.5% premium to the undisturbed price (HK$7.17 on 10 July).
The key condition is approval by at least 75% of disinterested shareholders (&lt;10% of all disinterested shareholders rejection). No independent shareholder holds a blocking stake. 
The offer price is final. While the offer price is light compared to peer multiples and historical share prices, the deal will likely succeed. 


IMAX China (1970 HK): IMAX Corp’s Privatisation Offer

<ul>
<li>This morning (13 July), <a href="https://www.smartkarma.com/entities/imax-china-holding-inc" target="_blank" data-smartkarma-citation="entities:888:1" rel="noopener">IMAX China Holding (1970 HK)</a> announced a take-private transaction from its parent <a href="https://www.smartkarma.com/entities/imax-corp" target="_blank" data-smartkarma-citation="entities:5321:1" rel="noopener">IMAX Corp (IMAX US)</a> at HK$10/share.</li>
<li>The Offer price is a 9.65% premium to last close but a 39.47% premium over the closing price on the last full trading day. Evidently, there was news leakage.</li>
<li>IMAX US holds  71.63% in IMAX China, therefore the blocking stake at the Schene Meeting is 2.837% of shares out. </li>
</ul>


This morning (13 July), IMAX China Holding (1970 HK) announced a take-private transaction from its parent IMAX Corp (IMAX US) at HK$10/share.
The Offer price is a 9.65% premium to last close but a 39.47% premium over the closing price on the last full trading day. Evidently, there was news leakage.
IMAX US holds  71.63% in IMAX China, therefore the blocking stake at the Schene Meeting is 2.837% of shares out. 


IMAX China (1970 HK): Parent Privatisation

Haitong International Securities Group / Event-Driven

<ul>
<li>For the month of October 2023, 7 new deals (firm and non-binding) were discussed on Smartkarma with an overall announced deal size of ~US$4bn.</li>
<li>The average premium for the new deals announced (or first discussed) in October was 65%. The average YTD is 37% (85 deals).</li>
<li>This compares to the average premium for all deals in 2022 (106 deals), 2021 (165 deals), 2020 (158 deals), and 2019 (145 deals) of 41%, 33%, 31%, and 31% respectively.</li>
</ul>


For the month of October 2023, 7 new deals (firm and non-binding) were discussed on Smartkarma with an overall announced deal size of ~US$4bn.
The average premium for the new deals announced (or first discussed) in October was 65%. The average YTD is 37% (85 deals).
This compares to the average premium for all deals in 2022 (106 deals), 2021 (165 deals), 2020 (158 deals), and 2019 (145 deals) of 41%, 33%, 31%, and 31% respectively.


(Mostly) Asia M&A, Oct 2023: Haitong, Azure, Hollysys, Aeon, Teraoka, Tietto, Lithium Power

Hong Kong

IMAX China Holding, Inc. operates as a holding company. The Company, through its subsidiaries, broadcasts movies in theaters. IMAX China Holding serves customers in China.

IMAX China Holding (1970 HK)

IMAX China (1970 HK): Risk as Scheme Vote on 10 October

The IMAX China scheme has failed. The minority participation rate was 60.93%. 70.0% of disinterested shareholders voted YES, and 18.28% of all...

Arun George

IMAX China (1970 HK)'s Offer: 10th Oct Shareholder Vote

Trading at a 4.9%/46.5% gross/annualised spread, reflecting the vote risk. If risky, illiquid arbs are your thing, buy here and on any weakness....

David Blennerhassett

IMAX China (1970 HK): IMAX Corp’s Privatisation Offer

The offer price is final. No independent shareholder holds a blocking stake. While the offer price is light compared to peer multiples and...

Arun George

IMAX China (1970 HK): Parent Privatisation

Trading at a 6.8%/21% gross/annualised spread, assuming mid-Nov completion. That's a little wider than you'd see in a cleaner deal. I still expect...

David Blennerhassett

(Mostly) Asia M&A, Oct 2023: Haitong, Azure, Hollysys, Aeon, Teraoka, Tietto, Lithium Power

For the month of October, 7 new deals were discussed on Smartkarma with an overall deal size of ~US$4bn. The average premium for the new deals...

David Blennerhassett